EUCTR2019-000136-26-DE进行中（未招募）1 期
Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation - MAURITIUS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 86
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with molecular relapse or persistent molecular positivity of AML after allogeneic SCT
- •Detection of FLT3-ITD or FLT3-TKD at primary diagnosis or at antecedent relapse of AML prior to allogeneic SCT
- •Sensitive MRD assessment based on qPCR (i.e. low PCR cut off” for each applied MRD marker of at least 0.1% - e.g. NPM1mut/ABL1)
- •ANC > 1,0 Gpt/L and Platelets > 50 Gpt/L
- •ECOG performance status 0-2
- •GFR > 30 ml/min and serum bilirubin < 1.5 x ULN
- •Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) = 3.0 × ULN;
- •Serum levels of potassium (3.3-4.5 mmol/L), magnesium (0.77-1.03 mmol/L), total calcium (2.2- 2.65 mmol/L) or within the normal limits (=LLN [lower limit of normal] and =ULN [upper limit of normal]) of the hospital or local laboratory. Correction of electrolytes levels with supplements to fulfil inclusion criteria is allowed.
- •All female patients with reproductive potential and all male patients must agree to use effective methods to prevent pregnancy. Female patients of childbearing potential must agree to use dual methods of contraception (i.e. with progesterone contraceptive implants, intrauterine device with progesterone, pills containing estrogen and progestin, as well as three-month injection with depot progestin) for the duration of the study. Male patients and male partners of female patients must agree to use a barrier method of contraception for the duration of the study if sexually active with a female of childbearing potential. It is required that sexually active men use condom during intercourse while taking the drug and for 2 weeks after stopping treatment and not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. Female partners of male patients must be advised to use a highly effective method of contraception. Contraception and a hold on sperm donation for male patients are to be continued for at least 2 weeks after the last dose of midostaurin for safety reasons.
- •All women of child-bearing potential have to complete a serum pregnancy test at screening visit. After screening, monthly serum pregnancy tests must be performed by all enrolled women of child-bearing potential from start of midostaurin until stop of midostaurin. If a test result indicates a pregnancy, the patient must stop treatment with midostaurin immediately. Pregnancy testing is not required for women who are determined to be post-menopausal.
- •Written informed consent prior to any study procedures being performed
- •Age = 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 29
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 57
排除标准
- •Acute promyelocytic leukemia (APL)
- •Hematological relapse of AML (bone marrow blasts =5% or reappearance of blasts in the blood or development of extramedullary disease)
- •Lack of a suitable MRD marker (no detectable MRD marker at diagnosis or low sensitivity of an available MRD marker, e.g. sensitivity > 0.1% MRD transcript/ABL1)
- •Impaired left ventricular ejection fraction (LVEF) < 45%
- •Patients with midostaurin treatment after allogeneic SCT or with ongoing TKI therapy < 4 weeks prior to inclusion
- •Treatment with an investigational drug within 5 half-lives preceding the first dose of study medication
- •History of acute or chronic pancreatitis
- •Active and uncontrolled infections
- •History of severe lung disease and/or relevant functional impairment
- •Positive PCR for Human Immunodeficiency Virus (HIV) or Hepatitis B or C
- •Patients unable to swallow medication
- •Known hypersensitivity reaction to midostaurin or any excipient of midostaurin
- •Concomitant medications with known induction of CYP3A4 isoenzyme unless they can be discontinued or replaced prior to enrollment
- •Patients who have undergone major surgery = 2 weeks prior to enrolment or who have not recovered from side effects of such therapy
- •Patients with resting QTcF =450 msec prior to enrolment or inability to determine the QTcF interval. Other clinically significant heart disease (e.g. unstable angina, congestive heart failure) Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol
- •Substance abuse, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results
研究者
相似试验
招募中
不适用
Acute myeloid leukemia and myelodysplatic syndrome: parenteral-, enteral- and only oral nutrition during remission induction treatmentAcute myeloid leukemia and late stage myelodysplastic syndromeNL-OMON20839Maxima MC180
招募中
2 期
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLChronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaNCT05184842Montefiore Medical Center91
进行中（未招募）
不适用
A phase III trial in adult acute myelogenous leukemia AML comparing 1 standard-dose versus high-dose remission induction therapy and 2 , within a risk-oriented postremission strategy, an autologous blood stem cell transplantation versus an autologous blood stem cell-supported multicycle high-dose program Protocol NILG-AML 02/06 . - NDPATIENT WHIT LMAMedDRA version: 8.1Level: HLTClassification code 10024291Term: Leukaemias acute myeloidEUCTR2006-003817-42-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE
已完成
4 期
Doxorubicin versus Idarubicin in Acute Myeloid LeukemiaHaematological DisordersCancerPACTR202309818279236ational Cancer Institute244
尚未招募
2 期
AMLM22/D3 - The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12621000246886Australian Leukaemia and Lymphoma Group (ALLG)50